Ge Long Hui·2025-12-05 09:44Core Viewpoint - Shanghai Pharmaceuticals (02607.HK) announced that its subsidiary, Shanghai Pharmaceuticals Dongying (Jiangsu) Co., Ltd., has received a drug registration certificate from the National Medical Products Administration for Minoxidil topical solution, allowing it to commence production [1] Group 1: Drug Approval - The Minoxidil topical solution has been approved for production as a Class A over-the-counter drug in accordance with the Drug Administration Law of the People's Republic of China [1] - The drug was originally developed by Johnson & Johnson, with the 2% formulation launched in the U.S. in 1988 and the 5% formulation in 1997 [1] Group 2: Indications and Usage - The 2% formulation is indicated for the treatment of male pattern baldness and alopecia areata, while the 5% formulation is restricted to male use for the same conditions [1] Group 3: Development and Competition - Shanghai Pharmaceuticals Dongying submitted the registration application for the drug to the National Medical Products Administration in January 2024, which has been accepted [1] - As of the announcement date, the company has invested approximately RMB 6.56 million in the research and development of this drug [1] - Major domestic manufacturers of this drug include Shanxi Zhendong Anxin Biopharmaceutical, Sichuan Meida Kanghua Pharmaceutical, and Shandong Jingwei Pharmaceutical [1]